CriticalFirst-generation antihistamine with anxiolytic activity×Non-selective beta blocker with class III antiarrhythmic activity
Updated · Methodology
Mechanism
Hydroxyzine is associated with QT prolongation. Post-marketing cases of QT prolongation and torsade de pointes occurred mostly in people with other risk factors, electrolyte disturbances or concomitant medicines (hydroxyzine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Sotalol is a beta-blocker with class III antiarrhythmic activity. It prolongs the QT interval and slows the heart rate, and a slow heart rate itself raises the risk of torsade de pointes (sotalol SmPC, AEMPS). The Spanish hydroxyzine SmPC names sotalol among the drugs that raise the risk of arrhythmia when taken with hydroxyzine. It also asks for special caution with drugs that slow the heart rate (AEMPS). The Spanish sotalol SmPC lists hydroxyzine among QT-prolonging drugs (sotalol SmPC, AEMPS). Sotalol undergoes no metabolism, and the kidneys excrete 80–90% of the dose unchanged. The documents describe no enzyme-mediated interaction for this pair (sotalol SmPC, AEMPS).
Symptoms
QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG). The most significant adverse reactions of sotalol are proarrhythmic effects, including torsade de pointes. Torsade de pointes usually starts after treatment begins or after a dose increase but can also occur later. It may stop on its own or come with fainting, and in rare cases it progresses to ventricular fibrillation (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of torsade de pointes is higher with a history of QT prolongation above 450 ms, a heart rate below 60 per minute, low potassium and magnesium, high sotalol levels after overdose or in kidney failure, other QT-prolonging drugs, and apparently in women (sotalol SmPC, AEMPS). Sotalol itself often causes a slow pulse, dizziness and fainting. The adverse reactions of hydroxyzine include QT prolongation, ventricular arrhythmias and loss of consciousness (sotalol and hydroxyzine SmPCs, AEMPS).
Management
The combination is contraindicated. The Spanish hydroxyzine summary of product characteristics (SmPC) contraindicates hydroxyzine with drugs that prolong the QT interval or cause torsade de pointes and names sotalol (hydroxyzine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The Spanish sotalol SmPC lists hydroxyzine among combinations it does not recommend and advises extreme caution when sotalol is given with QT-prolonging drugs (sotalol SmPC, AEMPS). The US sotalol label advises avoiding QT-prolonging drugs (sotalol label, US Food and Drug Administration, FDA), and the US hydroxyzine label recommends caution with sotalol (hydroxyzine label, FDA). Hydroxyzine is also contraindicated in known QT prolongation, cardiovascular disease, low potassium or magnesium, a family history of sudden cardiac death and significant bradycardia (hydroxyzine SmPC, AEMPS). Do not prescribe sotalol until low potassium or magnesium has been corrected (sotalol SmPC, AEMPS). Before treatment, record an electrocardiogram (ECG) and normalise potassium and magnesium (sotalol FDA label). During sotalol treatment, monitor the ECG at regular intervals. If QT or QRS lengthens by 25% or more, PQ by 50% or more, or QTc exceeds 480 ms, reassess benefit and risk and seriously consider reducing the dose or stopping sotalol. If the resting heart rate falls to 50–55 per minute with symptoms, reduce the dose (sotalol SmPC, AEMPS). If hydroxyzine and sotalol have nevertheless been taken together and signs of arrhythmia appear, stop hydroxyzine (hydroxyzine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Betapace / Betapace AF (sotalol hydrochloride) tablets – prescribing information (2024)– FDA label, Legacy Pharma USA, DailyMed setid a6a7702f-36c9-45db-b640-453dc324baee, version 2, 12/2024, sections 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Hidroxizina (nº registro 26308), sección 4.5 (2023)– AEMPS, CIMA, nº registro 26308 (Atarax 25 mg comprimidos recubiertos con película, UCB Pharma), revisión 02/2023, secciones 4.3, 4.4, 4.5 y 4.8
- FDA: Hydroxyzine Hydrochloride Tablets, USP (hydroxyzine) prescribing information (2026)– FDA, DailyMed setid 9de2de56-614f-4294-8794-d30758cf5f70 (Aurobindo Pharma), revisión 03/2026 (versión 2), Contraindications, Precautions (QT Prolongation/Torsade de Pointes), Overdosage
- AEMPS: Ficha técnica: Sotalol, Sotapor 80 mg (nº registro 62001), sección 4.5 (2022)– AEMPS, CIMA, nº registro 62001 (Sotapor 80 mg comprimidos, Cheplapharm), revisión 11/2022 (texto revisado 09/2022), secciones 4.3, 4.4, 4.5 y 5.2